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In the safety assessment of novel foods produced through
biotechnology, careful consideration is given to determining the
allergenic potential of newly introduced proteins. IgE serum
screening is one tool for evaluating whether the protein in question
has sequence identity to a known allergen or if the source of the
gene encoding the protein is a known allergenic food. A ‘‘specific’’
serum screen involves testing a gene product with sera from
patients with documented clinical allergy to a specific allergen to
confirm that the gene product of interest is not the same protein to
which the patient produces IgE antibodies. A ‘‘targeted’’ serum
screen involves testing the gene product of interest with sera from
patients sensitive to food or aeroallergens from the same broad
group. The concept of a global sera bank with accessible, well-
characterized sera for use in such assays is an appealing option.
This paper summarizes the consensus elements from a workshop
to evaluate the potential utility of an international sera bank for
evaluating the allergenicity of novel proteins. Areas of agreement
following the workshop included the following: (1) specific sera
screens are appropriate for exploring potentially cross-reactive
proteins that have been identified through bioinformatics ana-
lyses; however, additional validation is needed, particularly for
targeted sera screens, (2) practical and ethical considerations may
preclude the formation of a global sera bank, and therefore, (3)
a regional network of clinicians who could serve as sources of
patient sera or be approached to conduct sera studies would be the
most practical alternative.
Key Words: sera bank; allergenicity; serum screening; atopic
diseases.
INTRODUCTION
In recent years, there has been a considerable amount of
attention given to evaluating the safety of foods produced
through genetic modification using biotechnology. Foods that
have been produced using biotechnology have been transgen-
ically modified to achieve a number of characteristics including
insect and herbicide resistance and nutritional enhancement.
Such modifications result in the introduction of a new or
‘‘novel’’ protein into the food. As a result of these genetic
modifications, there is a need to comprehensively evaluate the
risk and safety associated with foods that have been modified
using biotechnology. A fundamental part of evaluating the risk
and safety associated with these foods is an allergenicity
evaluation of the newly expressed protein in the modified food
product.
Evaluating the potential allergenicity of novel proteins has
historically relied on a ‘‘weight-of-evidence’’ approach that con-
siders a number of factors including the source of the novel pro-
tein, the similarity of the amino acid sequence of the novel
protein to that of known allergens, and the stability of the novel
protein to heat and simulated gastric fluid. In cases where the
amino acid sequence of the novel protein was similar to that of
a known allergen, serum screening has been used to assess the
IgE reactivity of patients who have documented clinical allergy
to food allergens which have a similar amino acid sequence to
the novel protein.
In agreement with a previous recommendation (Metcalfe
et al., 1996), FAO/WHO (2000) suggested that specific serum
screening be conducted if the source of the novel gene was
a known allergenic food or aeroallergen and sera from patients
with that specific allergy would be used to confirm that the gene
product of interest was not the protein to which the patient
produced IgE antibodies. FAO/WHO further suggested that
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a targeted serum screen be conducted in all other cases. Codex
Alimentarius Commission (2003) elected not to support the
recommendations for targeted serum screening because its
usefulness had not been practically demonstrated. Furthermore,
the utility of serum screening in the absence of sufficient
structural similarity between the protein of interest and a known
allergen as recommended by Thomas et al. (2005) (e.g., at
a level of 35% over 80 or greater amino acids) has not been
rigorously tested.
The availability of serum from well-characterized (i.e.,
clinically relevant) allergic patients is essential for successful
serum testing. Thus, there would be substantial utility for an
international serum bank, which could be used for novel protein
safety testing. Accordingly, the International Life Sciences
Institute (ILSI) Health and Environmental Sciences Institute
(HESI) Protein Allergenicity Technical Committee organized
a workshop in April 2006 to discuss the potential utility of an
international sera bank for evaluating the allergenicity of novel
proteins with sera from food allergic patients. The purpose of
this paper is to summarize the workshop discussions associated
with the development of an international sera bank for
evaluating novel proteins. These discussions included a review
of patient diagnostic criteria for inclusion in a sera bank, the
appropriate application of serum testing, the logistical and
management issues associated with serum banks, and the use of
in vitro and in vivo testing to make decisions about the inclusion
of sera in a bank.
FOOD ALLERGY—CLINICAL BACKGROUND, ATOPIC
INDIVIDUALS, AND DIAGNOSTIC CRITERIA FOR
INCLUSION IN A SERA BANK
Atopic diseases such as food allergy, asthma, and atopic
dermatitis (AD) are characterized by IgE sensitization to
foreign proteins. Atopy refers to an individual being prone to
develop allergic disease due to a genetic state of hyper-
responsiveness to mount IgE responses to common allergens.
A food allergy is a specific immunologic reaction to an
otherwise harmless food component, and the majority of these
reactions are classified as a type I hypersensitivity reaction that
is mediated by IgE antibody. The classical clinical symptoms of
IgE-mediated food allergy, local reactions such as swelling of
the tongue or oral mucosa, or systemic reactions such as
urticaria or vomiting appear within minutes to 2 h following
each ingestion of the offending substance. The skin, the
gastrointestinal tract, respiratory tract, and cardiovascular
system are the primary target organs in food allergy (Sicherer,
2000). The oral allergy syndrome is the most frequent clinical
presentation of food allergy seen in adult patients (Mari et al.,
2005). A minority of food allergy reactions are cell mediated,
rather than IgE mediated, but both are distinct from food
intolerances which are not immune mediated.
Food allergy affects up to 8% of children and 2–4% of adults
(Osterballe et al., 2005; Zuberbier et al., 2004). However, the
prevalence of food allergy is estimated to be much higher by the
general population (perceived vs. true food allergy symptoms).
Therefore, an accurate clinical history of consistent allergic
reactions to the food, coupled with carefully selected allergy
tests that support the history, is essential to identify appropriate
patients whose sera would be included in a sera bank. The gold
standard for definitively diagnosing food allergy is a double-
blind, placebo-controlled food challenge (DBPCFC): allergy
skin prick tests and IgE Radio Allergosorbent Tests (RASTs)
only suggest the diagnosis of food allergy.
AD is a chronic inflammatory skin disease that affects up to
10% of children. Approximately 30–40% of children with
moderate to severe AD also have food allergy that has been
confirmed with DBPCFC. For most patients with AD, the total
serum IgE and allergen-specific IgE levels may be markedly
elevated, but exposure to the allergens often does not result in
clinical symptoms. These patients have asymptomatic sensiti-
zation and must be differentiated from those with true allergy
for the purposes of sera-screening studies. Only sera from
patients who demonstrate classical symptoms of food allergy
and who have positive allergy tests to the food in question
should be included in sera banks used to evaluate novel
proteins. The sera is further designated as ‘‘specific’’ if it is
used to test the allergenicity of novel proteins derived from the
‘‘same’’ food or a cross-reacting protein to which the serum
donor was allergic, not merely sensitized. In contrast, ‘‘tar-
geted’’ serum testing evaluates the allergenicity of novel
proteins derived from foods ‘‘similar’’ (i.e., to the same broad
group) to the food causing the serum donor’s food allergy.
APPLICATIONS OF SERUM SCREENING
Two case studies where a limited targeted serum screen was
employed using a bank composed of sera from Danish allergic
patients provide practical examples of the application of serum
screening. The first case examines the potential allergenicity of
the Nangai nut (Canarium indicum) prior to allowing import
into Europe (Poulsen, 2004; Sten et al., 2002). In this case,
a targeted sera screen was performed using sera from patients
allergic to pollen (from mugwort, birch, grass, etc.) or cat or dog
dander. The results showed positive IgE reactions by using
several tests. For instance, 13% of the patients tested showed
IgE specificity to Nangai nut by histamine release assays and
17% showed IgE specificity to RAST. In addition, open food
challenges were performed, with 3 out of 12 patients tested with
Nangai showing a positive response. The Nangai nut was
classified as a presumptive allergen based on these in vitro
and in vivo tests. However, using DBPCFC tests, this could not
be confirmed in two patients. As it turned out, the proposal
to import the Nangai nut was abandoned because of other
food safety problems, specifically mycotoxin contamination.
In the second case study, a microbial transglutaminase iso-
lated from the organism Streptoverticillium mobaraense had
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a 5 contiguous amino acid identity to the major codfish allergen,
heat stable allergen Gad c1. Among the 25 fish allergic sera,
no binding between patient IgE and transglutaminase was
observed (Pedersen et al., 2004).
Therefore, although sera showing positive reactions in vitro
to a food or an inhaled allergen may be used for studying the
degree and the character of cross-reactivity between a known
allergen and a novel protein, it is suggested that only sera from
clinically reactive patients (i.e., well-characterized sera) are
actually used to perform risk evaluations. Other classes of sera
may still be interesting and relevant for outlining the type of
cross-reactivity between a known allergen and a novel protein;
however, they may contain IgE antibodies of low biological
activity or low clinical relevance. In these examples, the tar-
geted serum screen did not add significant value to the allergy
safety assessment. Consequently, the utility of targeted sera
screens needs to be further investigated and validated before it
is broadly used in the safety assessment of novel proteins.
SERA BANKS
Different organizations around the world have developed or
proposed the development of sera banks containing the sera
from allergic patients. There appears, however, to be different
motivations for developing these sera banks such as (1) to
increase the understanding of food allergies, (2) to better
understand the prevalence and distribution of specific allergies,
(3) to predict whether the inclusion of a novel protein or novel
food in the food supply will result in the development of new
allergies or whether the protein will be cross-reactive with
existing allergens, (4) to identify specific allergens, and (5) for
use in postmarketing surveillance strategies to monitor the
potential for development of reactivity to newly introduced
foods. These different motivations impact the design of the sera
bank and especially the selection of patients whose sera are to
be included.
Arguably, the most advanced regional sera banks are located
in Europe and South Korea. The goal for the European (i.e.,
EuroPrevall) Serum Bank is to investigate the prevalence and
distribution of food allergies throughout Europe in infants,
children, and adults. More specifically, the project intends to
determine the threshold doses for different allergenic foods,
investigate the role of the environment in determining the
different patterns of food allergy, measure the socioeconomic
impact of food allergy, and develop new diagnostic tools to
provide a better correlation of in vitro diagnostic results with
the clinical situation. The EuroPrevall Sera Bank has strict
criteria for inclusion of patient sera. For example, six different
case record forms, including information on clinical history,
skin prick tests to 42 different commercial extracts, and food
challenge studies must be completed for each patient. There are
plans to evaluate approximately 70,000 subjects within the
different substudies of EuroPrevall. The EuroPrevall project
involves 20 mostly European countries and 54 partners. A key
element in this project is the development of a clinical databank
with standardized reporting and collection of data allowing
clinical patterns to be identified.
The Korean Sera Bank was developed to facilitate population
monitoring for reactivity to commercially available products
produced through biotechnology (i.e., postmarketing surveil-
lance) as well as to evaluate products seeking approval using
targeted and specific sera-screening methods. The Korean Sera
Bank is being constructed in two phases involving 10 branch
centers throughout Korea. In the first phase, sera from patients
with allergy symptoms to a variety of sources (e.g., house dust,
pollen, mold, food including egg white, milk, soy, corn, wheat,
tomato, potato, rice, sesame, red pepper, etc.) that gave
a positive skin test or reacted positively in a CAP Fluorescent
Enzyme Immunoassay were included. Confirmation of the
clinical reactivity of the serum donors by challenge tests has not
been performed in the majority of cases. Currently, 1434 sera
samples have been collected with a subset of 237 sera available
for use in monitoring the development of allergies in response
to exposure to products produced through biotechnology. In the
second phase, the sera will be further classified, although details
on the further classification of the sera had not been developed.
As noted above, not only are the purposes of the two sera
banks different but also are the criteria for inclusion of sera in
the two sera banks different, with the EuroPrevall Sera Bank
having more stringent criteria for sera inclusion than that
required for the Korean Sera Bank. To maximize the potential
for informing the safety assessment of novel proteins, sera used
in such studies should have significant clinical documentation.
The ‘‘gold standard’’ for inclusion of patient sera is clinical
reactivity confirmed by DBPCFC. In lieu of DBPCFC, which is
not always possible to conduct, criteria for serum inclusion
should include a convincing history of clinical allergic reac-
tions to a specific allergen. In the case of anaphylactic reactions
where challenges cannot be performed, clinical reactivity can
be evaluated using IgE-binding studies and biological activity
assays (e.g., histamine release assays; skin prick tests) (Table 1).
Although a sera bank would be useful to track the de-
velopment and prevalence of allergies over time and to study
the properties of food allergens, the development of a centrally
located sera bank may be impractical for a variety of reasons.
There are many unresolved questions regarding the funding and
maintenance of such a bank, what would happen to the sera in
the bank if funding was eliminated (i.e., who owned the sera?),
and who would have access to such sera. There are also ethical
questions related to the use of the sera for research and com-
mercial purposes. Often, sera are obtained for research pur-
poses exclusively and are restricted from being used for
commercial purposes. There are further concerns around which
clinical allergies should be represented in the bank (e.g., should
they be regionally based, ethnically based, include allergy to
just the major food allergens or be more broadly based to in-
clude all foods, aeroallergens, and insect venoms, i.e., like those
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contained in allergen databases?). Ultimately, a sera bank
should contain clinically documented sera from as many known
allergens as possible, but the above-mentioned practical and eth-
ical concerns would make it extremely difficult to implement.
The formation of a network of clinicians from each region of
the world who could be used as a resource for identifying sera
and conducting sera studies would be a reasonable alternative
to developing an international sera bank.
IGE TESTING—HOW TO USE IN VITRO AND IN VIVO
TESTING TO MAKE DECISIONS ABOUT
INCLUSION OF SERA
Sera from allergic patients are of interest because of the
allergen-specific IgE molecules they contain. They can be used
as reagents in various analyses with proteins of interest to make
an assessment of potential cross-reactivity. However, while
specific IgE is necessary to cause allergic disease, it is not
sufficient to trigger the allergic cascade unless at least two IgE-
binding epitopes are available within the allergen. Additionally,
there must be high avidity between the IgE and the epitope,
sufficiently abundant IgE, and exposure to the allergen in order
to elicit a clinical food allergic reaction.
The biological versus clinical relevance of IgE-binding
assays is critically important. Distinguishing allergen-specific
IgE from total IgE is relatively easy, while it is much more
difficult to distinguish clinically relevant IgE binding from
specific IgE binding with little or no correlation to clinical
symptoms. For instance, a high frequency of IgE binding to
fruits, nuts, and vegetables is observed in birch pollen allergic
subjects without food allergy (see, e.g., Reuter et al., 2006) or
to wheat in grass pollen allergic subjects without food allergy
to cereals (Jones et al., 1995). This lack of clinical relevance of
many positive IgE-binding tests may be explained by the fact
that the biological activity of an IgE molecule is mainly
determined by the avidity of the allergen-specific IgE and by
the epitope valency. In practice, these antibodies are at the basis
of many false positive results for food allergy in diagnostic
tests. On the contrary, the absence of IgE binding to a given
food has a high negative predictive value, provided that a high-
quality allergen preparation is used for testing.
IgE test methods include in vitro assays such as dot blot
(microarray), immunoblot (may be done under reducing, non-
reducing, native, or two-dimensional conditions), Enzyme-
Linked ImmunoSorbent Assay, basophil histamine release
assays, RAST, EAST, or inhibition assays (Poulsen et al.,
2006). Skin prick tests and DBPCFC are examples of in vivo
IgE-binding methods. The IgE tests must be validated in terms
of sensitivity of IgE detection (detection limit) and isotype
specificity (e.g., cross-reactivity of the detection system with
IgG) and general method performance characteristics such as
inter- and intra-assay variation. They must include positive and
negative control sera and must include positive and negative
control proteins and extracts. Serum donors must be selected
with relevant, clinically proven allergies. Validation of the IgE
test establishes reproducibility from day to day, analyst to
analyst, and among different extract preparations. A limit of
detection should be established as well as a limit of quantitation
and positive cutoff values. There is not a clear consensus
regarding which assay is preferable for sera characterization.
However, the more physiologically relevant methods, such as
histamine release assays or basophil activation tests, provide
greater insight into whether IgE reactivity of a serum would be
of clinical significance.
CONCLUSION
The use of sera banks to facilitate specific serum screens is
scientifically defensible, but there are practical limitations
because these screens only detect antigen-specific IgE binding,
which is not necessarily representative of clinically relevant
allergic response. The targeted serum screen is more contro-
versial as a result of its lack of validation and unknown utility
for risk assessment and safety testing.
Specific serum screens may also play a role in exploring
potentially cross-reactive proteins that have been identified
through bioinformatics analyses when they utilize well-
characterized patient sera. However, the utility of serum-
screening tests, particularly targeted serum screens, for risk
and safety evaluations should be further investigated and
validated. While the concept of sera banks that could supply
clinically well-documented patient sera for testing the potential
allergenicity of novel proteins is attractive, there are practical
and ethical considerations that may preclude this from be-
coming reality. Consequently, the formation of a network of
clinicians from each region of the world who could be utilized
to conduct sera studies or, alternatively, would serve as sources
of sera from appropriately characterized patients would be the
most beneficial and best path forward.
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